MCID: ALP048
MIFTS: 32

Alopecia Totalis

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Alopecia Totalis

MalaCards integrated aliases for Alopecia Totalis:

Name: Alopecia Totalis 53 59 73
Loss of All Scalp Hair 53

Characteristics:

Orphanet epidemiological data:

59
alopecia totalis
Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare skin diseases


External Ids:

Orphanet 59 ORPHA700
UMLS via Orphanet 74 C0263504
ICD10 via Orphanet 34 L63.0
ICD10 33 L63.0
SNOMED-CT via HPO 69 278040002 298000004 56317004
UMLS 73 C0263504

Summaries for Alopecia Totalis

NIH Rare Diseases : 53 Alopecia totalis (AT) is a condition characterized by the complete loss of hair on the scalp. It is an advanced form of alopecia areata a condition that causes round patches of hair loss. Although the exact cause of AT is unknown, it is thought to be an autoimmune condition in which the immune system mistakenly attacks the hair follicles. Roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of AT. There is currently no cure for AT, but sometimes hair regrowth occurs on it's own, even after many years.

MalaCards based summary : Alopecia Totalis, also known as loss of all scalp hair, is related to alopecia areata and t-cell immunodeficiency, congenital alopecia, and nail dystrophy. An important gene associated with Alopecia Totalis is TMPO (Thymopoietin). The drugs Hydroxychloroquine and Orange have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and thyroid, and related phenotypes are alopecia and alopecia of scalp

Wikipedia : 76 Alopecia totalis is the loss of all skull and facial hair. Its causes are unclear, but believed to be... more...

Related Diseases for Alopecia Totalis

Graphical network of the top 20 diseases related to Alopecia Totalis:



Diseases related to Alopecia Totalis

Symptoms & Phenotypes for Alopecia Totalis

Human phenotypes related to Alopecia Totalis:

59 32
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 alopecia 59 Very frequent (99-80%)
2 alopecia of scalp 32 hallmark (90%) HP:0002293
3 scalp hair loss 59 Very frequent (99-80%)

Drugs & Therapeutics for Alopecia Totalis

Drugs for Alopecia Totalis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 4 118-42-3 3652
2 Orange Approved Phase 4
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
8 Antirheumatic Agents Phase 4,Phase 2,Not Applicable
9 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
10 Antiprotozoal Agents Phase 4
11 Antiparasitic Agents Phase 4
12 Antimalarials Phase 4
13 Antineoplastic Agents, Hormonal Phase 4
14 Anti-Inflammatory Agents Phase 4,Not Applicable
15 Antiemetics Phase 4
16 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
17 Prednisolone acetate Phase 4
18 Gastrointestinal Agents Phase 4
19 glucocorticoids Phase 4
20 Hormone Antagonists Phase 4
21 Methylprednisolone acetate Phase 4
22 Neuroprotective Agents Phase 4
23 Autonomic Agents Phase 4
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
25 Hormones Phase 4
26 Protective Agents Phase 4,Phase 2,Phase 3
27
Acetylcholine Approved Phase 2, Phase 3 51-84-3 187
28
Bexarotene Approved, Investigational Phase 2, Phase 3 153559-49-0 82146
29 onabotulinumtoxinA Phase 2, Phase 3
30 Neuromuscular Agents Phase 2, Phase 3
31 Cholinergic Agents Phase 2, Phase 3
32 abobotulinumtoxinA Phase 2, Phase 3
33 Acetylcholine Release Inhibitors Phase 2, Phase 3
34 Neurotransmitter Agents Phase 2, Phase 3
35 Botulinum Toxins Phase 2, Phase 3
36 Botulinum Toxins, Type A Phase 2, Phase 3
37
Abatacept Approved Phase 2 332348-12-6 10237
38
Tofacitinib Approved, Investigational Phase 2,Not Applicable 477600-75-2
39
Cidofovir Approved Phase 2 113852-37-2 60613
40 Immunologic Factors Phase 2,Not Applicable
41 Immunosuppressive Agents Phase 2,Not Applicable
42 Pharmaceutical Solutions Phase 2
43 Protein Kinase Inhibitors Phase 2,Not Applicable
44 Antiviral Agents Phase 2
45 Immunoglobulins Phase 2
46 Antibodies, Monoclonal Phase 2
47 Antibodies Phase 2
48 Anti-Bacterial Agents Phase 2,Not Applicable
49 Gentamicins Phase 2
50
Apremilast Approved, Investigational Not Applicable 608141-41-9 11561674

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
2 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
3 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Not yet recruiting NCT03800979 Phase 4 Tofacitinib
4 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
5 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
6 PF-06651600 for the Treatment of Alopecia Areata Recruiting NCT03732807 Phase 2, Phase 3 PF-06651600 Induction Dose;PF-06651600 Maintenance Dose #1;PF-06651600 Maintenance Dose #2;PF-06651600 Maintenance Dose #3;Placebo
7 An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata Unknown status NCT02018042 Phase 2 Abatacept
8 Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata Completed NCT03551821 Phase 2 ATI-50002
9 A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Completed NCT02684097 Phase 2 Tralokinumab;Placebo
10 Tofacitnib for the Treatment of Alopecia Areata and Variants Completed NCT02197455 Phase 2 Tofacitinib Administration
11 Trial of Topical Cidofovir for the Prevention of Hair Growth Completed NCT00948506 Phase 2 1% topical cidofovir;3% topical cidofovir;Placebo
12 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Recruiting NCT03359356 Phase 2 Dupilumab;Placebos
13 ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis Active, not recruiting NCT03594227 Phase 2 ATI-501 Low dose;ATI-501 Mid dose;ATI-501 high dose;Placebos
14 Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) Active, not recruiting NCT03315689 Phase 2 Vehicle;ATI-50002
15 Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants Active, not recruiting NCT02812342 Phase 2 Tofacitinib ointment
16 Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Active, not recruiting NCT02299297 Phase 2 Tofacitinib
17 ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) Not yet recruiting NCT03759340 Phase 2 ATI 502 0.46% Topical Solution
18 Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata Not yet recruiting NCT03532958 Phase 2 BNZ-1;Normal saline
19 Efficacy of Topical Gentamycin for Hereditary Hypotrichosis Simplex Caused by Nonsense Mutations in CDSN Not yet recruiting NCT03492866 Phase 2 Gentamicin Sulfate
20 A Study of Secukinumab for the Treatment of Alopecia Areata Terminated NCT02599129 Phase 2 Secukinumab;Placebo
21 A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) Terminated NCT02553330 Phase 2 Placebo Cream;INCB018424 Phosphate Cream
22 Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis Withdrawn NCT01314495 Phase 2 Abatacept;Inactive infusion
23 Efalizumab in the Treatment of Alopecia, Phase II Withdrawn NCT00746980 Phase 2 efalizumab
24 Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed NCT02312882 Not Applicable Tofacitinib
25 Alopecia Areata Registry Active, not recruiting NCT00069589
26 Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata Active, not recruiting NCT02684123 Not Applicable Apremilast;Placebo
27 Ocular Finding in Alopecia Areata Not yet recruiting NCT03155958

Search NIH Clinical Center for Alopecia Totalis

Genetic Tests for Alopecia Totalis

Anatomical Context for Alopecia Totalis

MalaCards organs/tissues related to Alopecia Totalis:

41
Skin, Bone, Thyroid, Testes, Bone Marrow, T Cells

Publications for Alopecia Totalis

Articles related to Alopecia Totalis:

(show top 50) (show all 73)
# Title Authors Year
1
Is methotrexate an effective and safe treatment for maintaining hair regrowth in people with alopecia totalis? A critically appraised topic. ( 29777625 )
2018
2
Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. ( 29754888 )
2018
3
Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. ( 29679494 )
2018
4
Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study. ( 30281139 )
2018
5
Hair Regrowth in a Patient With Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab. ( 30304403 )
2018
6
Multi-Concentration Level Patch Test Guided Diphenyl Cyclopropenone (DPCP) Treatment in Alopecia Totalis or Alopecia Universalis. ( 29911776 )
2017
7
Review of treatment for alopecia totalis and alopecia universalis. ( 28378336 )
2017
8
Long-Term Prognosis of Alopecia Totalis and Alopecia Universalis: A Longitudinal Study with More than 10 Years of Follow-Up: Better than Reported. ( 28704810 )
2017
9
Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: A case series of 8 patients. ( 27051848 )
2016
10
Treatment of corticosteroid-refractory alopecia totalis with oral tacrolimus. ( 27826988 )
2016
11
Pulse corticosteroid therapy with oral dexamethasone for the treatment of adult alopecia totalis and universalis. ( 27085229 )
2016
12
Nail lichen planus in a patient with alopecia totalis. ( 25526340 )
2014
13
Persistent and diffuse hair graying after recovery from alopecia totalis. ( 22591311 )
2014
14
Alopecia totalis in monosomy 18p. ( 24413381 )
2014
15
Recurrent spontaneous abortions, Hashimoto thyroiditis and alopecia totalis: response to anticoagulation and intravenous immunoglobulin therapy. ( 24308767 )
2014
16
Hepatitis C treatment and alopecia totalis. ( 24326562 )
2013
17
Successful treatment of alopecia totalis with hydroxychloroquine: report of 2 cases. ( 23680203 )
2013
18
Clinical characteristics and prognostic factors in early-onset alopecia totalis and alopecia universalis. ( 22787378 )
2012
19
Chronic inflammatory demyelinating polyneuropathy associated with alopecia totalis and SjAPgren syndrome. ( 22499108 )
2012
20
Photodynamic therapy with methyl 5-aminolevulinate acid might be ineffective in recalcitrant alopecia totalis regardless of using a microneedle roller to increase skin penetration. ( 20384755 )
2010
21
Turban PUVASOL: An Effective Treatment in Alopecia Totalis. ( 21712898 )
2010
22
Primary hypergonadotrophic hypogonadism, alopecia totalis, and mA1llerian hypoplasia: a clinical study. ( 19757710 )
2009
23
The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis. ( 18154427 )
2008
24
The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. ( 17010743 )
2006
25
Acute alopecia totalis. ( 16850096 )
2006
26
Alopecia totalis incognito. ( 15569019 )
2004
27
Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. ( 12833016 )
2003
28
Ineffectiveness of imiquimod therapy for Alopecia Totalis/Universalis. ( 12224709 )
2002
29
Antibodies against hair follicles are associated with alopecia totalis in autoimmune polyendocrine syndrome type I. ( 10594751 )
1999
30
The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis. ( 10674369 )
1999
31
Syndrome of alopecia totalis and 17b-hydroxysteroid dehydrogenase deficiency. ( 9508060 )
1998
32
Myasthenia gravis with alopecia totalis. ( 9583214 )
1998
33
Alopecia totalis treated with oral mini-pulse (OMP) therapy with betamethasone. ( 20947995 )
1996
34
Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. ( 8708020 )
1996
35
HLA class II alleles in long-standing alopecia totalis/alopecia universalis and long-standing patchy alopecia areata differentiate these two clinical groups. ( 7738393 )
1995
36
Alopecia totalis and topical mustine. ( 8466230 )
1993
37
Treatment of alopecia totalis with a combination of inosine pranobex and diphencyprone compared to each treatment alone. ( 1718636 )
1991
38
Alopecia totalis: is treating nonresponder patients useful? ( 2061445 )
1991
39
Alopecia totalis and vitiligo in common variable immunodeficiency. ( 2062780 )
1991
40
Thyroid antibodies in alopecia totalis. ( 1813129 )
1991
41
Simultaneous primary infection with HIV and CMV leading to severe pancytopenia, hepatitis, nephritis, perimyocarditis, myositis, and alopecia totalis. ( 2156107 )
1990
42
Successful bone marrow transplant and re-growth of hair in a patient with posthepatic aplastic anemia complicated by alopecia totalis. ( 2126659 )
1990
43
Allergic and irritant contact dermatitis compared in the treatment of alopecia totalis and universalis. A comparison of the value of topical diphencyprone and tretinoin gel. ( 2713259 )
1989
44
Alopecia totalis in a patient with Crohn's disease and its treatment with azathioprine. ( 2813243 )
1989
45
Induction of hair growth in alopecia totalis with diphencyprone sensitization. ( 2598490 )
1989
46
A randomized double-blind study of inosiplex (isoprinosine) therapy in patients with alopecia totalis. ( 2438319 )
1987
47
Alopecia totalis in a chimpanzee. ( 6502684 )
1984
48
An open-label trial of immunomodulation therapy with inosiplex (Isoprinosine) in patients with alopecia totalis and cell-mediated immunodeficiency. ( 6207216 )
1984
49
Alopecia totalis as a presentation of cutaneous metastasis (alopecia neoplastica). ( 6642837 )
1983
50
PUVA treatment of alopecia totalis. ( 6198849 )
1983

Variations for Alopecia Totalis

Expression for Alopecia Totalis

Search GEO for disease gene expression data for Alopecia Totalis.

Pathways for Alopecia Totalis

GO Terms for Alopecia Totalis

Sources for Alopecia Totalis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....